$RLFTF (related) $NRXP ZYESAMI™ (Aviptadil aceta
Post# of 653
(Total Views: 376)
Posted On: 06/26/2021 10:48:21 PM
$RLFTF (related) $NRXP ZYESAMI™ (Aviptadil acetate), a synthetic form of human Vasoactive Intestinal Peptide, an endogenous substance produced by the body that amongst other functions helps protect cells against inflammatory conditions.
(VIP) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA)for the treatment of Critical COVID-19 with respiratory failure, and is now in clinical trials.
Rapid recovery from Critical COVID-19 with respiratory failure has been reported in patients treated with open label VIP under an FDA Emergency Use IND and/or the Expanded Access program.
It must also be noted that Administered as an intravenous infusion the key side effects seen in the Expanded Access Program as well as the placebo controlled trial are diarrhea (~ in 1/3 of patients), hypotension (lowering of blood pressure). Emerging data indicates that VIP binds uniquely to receptors on Alveolar Type II cells in the lung, the same cells that bind the SARS-CoV-2 virus via their ACE2 receptors.
VIP protects those cells and the surrounding pulmonary epithelium by blocking cytokines, preventing cytopathy (cell death), and upregulating the production of surfactant, the loss of which is increasingly implicated in COVID-19 respiratory failure. Furthermore, emerging preclinical data suggests that VIP inhibits the replication of the SARS-CoV2 virus. https://www.nrxpharma.com/
(VIP) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA)for the treatment of Critical COVID-19 with respiratory failure, and is now in clinical trials.
Rapid recovery from Critical COVID-19 with respiratory failure has been reported in patients treated with open label VIP under an FDA Emergency Use IND and/or the Expanded Access program.
It must also be noted that Administered as an intravenous infusion the key side effects seen in the Expanded Access Program as well as the placebo controlled trial are diarrhea (~ in 1/3 of patients), hypotension (lowering of blood pressure). Emerging data indicates that VIP binds uniquely to receptors on Alveolar Type II cells in the lung, the same cells that bind the SARS-CoV-2 virus via their ACE2 receptors.
VIP protects those cells and the surrounding pulmonary epithelium by blocking cytokines, preventing cytopathy (cell death), and upregulating the production of surfactant, the loss of which is increasingly implicated in COVID-19 respiratory failure. Furthermore, emerging preclinical data suggests that VIP inhibits the replication of the SARS-CoV2 virus. https://www.nrxpharma.com/
(0)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
Scroll down for more posts ▼